Publications

List of Publications from Recent Years

PubMed

2025

1.         Xing YL, Panovska D, Park JW, Grossauer S, Koeck K, Bui B, Nasajpour E, Nirschl JJ, Feng ZP, Cheung P, Habib P, Wei R, Wang J, Thomason W, Monje M, Xiu J, Beck A, Weber KJ, Harter PN, Lim M, Mahaney KB, Prolo LM, Grant GA, Ji X, Walsh KM, Mulcahy Levy JM, Hambardzumyan D, Petritsch CK. BRAF/MEK inhibition induces cell state transitions boosting immune checkpoint sensitivity in BRAF(V600E)-mutant glioma. Cell Rep Med. 2025;6(6):102183. Epub 20250612. doi: 10.1016/j.xcrm.2025.102183. PubMed PMID: 40505659; PMCID: PMC12208339.

2.         Soni N, Rawat K, Chen Z, DiMauro A, Giotti B, Hambardzumyan D, Tsankov AM. Single-cell dissection of the genotype-immunophenotype relationship in glioblastoma. Brain. 2025;148(9):3153-69. doi: 10.1093/brain/awaf129. PubMed PMID: 40215269; PMCID: PMC12404732.

3.         Slocum CC, Nguyen P, Vij M, Yong RL, Samanamud J, Hiya S, Maldonado-Diaz C, Umphlett M, Silva-Hurtado TJ, Hatanpaa KJ, Viapiano MS, Snuderl M, Abdullah KG, McBrayer SK, Hambardzumyan D, Walker JM, Tsankova NM, Richardson TE. EGFR alteration is an adverse prognostic factor in IDH-mutant astrocytoma. Acta Neuropathol. 2025;150(1):20. Epub 20250819. doi: 10.1007/s00401-025-02928-w. PubMed PMID: 40828325; PMCID: PMC12364977.

4.         Seblani M, Zannikou M, Duffy JT, Joshi T, Levine RN, Thakur A, Puigdelloses-Vallcorba M, Horbinski CM, Miska J, Hambardzumyan D, Becher OJ, Balyasnikova IV. IL13RA2-integrated genetically engineered mouse model allows for CAR T cells targeting pediatric high-grade gliomas. Acta Neuropathol Commun. 2025;13(1):69. Epub 20250402. doi: 10.1186/s40478-025-01991-4. PubMed PMID: 40176156; PMCID: PMC11963683.

5.         Li J, Shih LK, Markwell SM, Olson CL, Sullivan DP, Arvanitis C, Ross JL, Lam NG, Nuszen H, Hambardzumyan D, Becher OJ, Brat DJ. A clinically relevant model and method to study necrosis as a driving force in glioma restructuring and progression. Proc Natl Acad Sci U S A. 2025;122(7):e2416024122. Epub 20250213. doi: 10.1073/pnas.2416024122. PubMed PMID: 39946540; PMCID: PMC11848380.

6.         Garcia-Fabiani MB, Haase S, Banerjee K, Zhu Z, McClellan BL, Mujeeb AA, Li Y, Tronrud CE, Varela ML, West MEJ, Yu J, Kadiyala P, Taher AW, Nunez FJ, Alghamri MS, Comba A, Mendez FM, Nicola Candia AJ, Salazar B, Nunez FM, Edwards MB, Qin T, Cartaxo RT, Niculcea M, Koschmann C, Venneti S, Vallcorba MP, Nasajpour E, Pericoli G, Vinci M, Kleinman CL, Jabado N, Chandler JP, Sonabend AM, DeCuypere M, Hambardzumyan D, Prolo LM, Mahaney KB, Grant GA, Petritsch CK, Welch JD, Sartor MA, Lowenstein PR, Castro MG. H3.3-G34R Mutation-Mediated Epigenetic Reprogramming Leads to Enhanced Efficacy of Immune Stimulatory Gene Therapy in Diffuse Hemispheric Gliomas. bioRxiv. 2025. Epub 20250205. doi: 10.1101/2023.06.13.544658. PubMed PMID: 37398299; PMCID: PMC10312611.

7.         Crowell C, Zhu Z, Li Y, Varela ML, Ostrom Q, Cimino PJ, Patel SH, Baker SJ, Bettegowda C, Noushmehr H, Kleinman CL, Canty L, Cruzeiro GAV, Nellan A, Becher O, Davidson TB, Hambardzumyan D, Green A, Thorne R, Wilson K, Theeler B, Gregory J, Mathen P, Biassou N, McThenia S, Erker C, Galvin R, Soldatos A, Lowenstein PR, Castro MG, Jackson S. A review of diffuse hemispheric glioma, H3 G34-mutant disease development, DNA repair, microenvironment, and treatments on the horizon. NPJ Precis Oncol. 2025;9(1):283. Epub 20250814. doi: 10.1038/s41698-025-01070-w. PubMed PMID: 40813437; PMCID: PMC12354862.

8.         Bairakdar MD, Lee W, Giotti B, Kumar A, Stancl P, Wagenblast E, Hambardzumyan D, Polak P, Karlic R, Tsankov AM. Learning the cellular origins across cancers using single-cell chromatin landscapes. Nat Commun. 2025;16(1):8301. Epub 20250917. doi: 10.1038/s41467-025-63957-3. PubMed PMID: 40962882; PMCID: PMC12443996.

2024

9.         Zarco N, Dovas A, de Araujo Farias V, Nagaiah NKH, Haddock A, Sims PA, Hambardzumyan D, Meyer CT, Canoll P, Rosenfeld SS, Kenchappa RS. Resistance to spindle inhibitors in glioblastoma depends on STAT3 and therapy induced senescence. iScience. 2024;27(12):111311. Epub 20241105. doi: 10.1016/j.isci.2024.111311. PubMed PMID: 39640583; PMCID: PMC11617384.

10.       Ross JL, Puigdelloses-Vallcorba M, Pinero G, Soni N, Thomason W, DeSisto J, Angione A, Tsankova NM, Castro MG, Schniederjan M, Wadhwani NR, Raju GP, Morgenstern P, Becher OJ, Green AL, Tsankov AM, Hambardzumyan D. Microglia and monocyte-derived macrophages drive progression of pediatric high-grade gliomas and are transcriptionally shaped by histone mutations. Immunity. 2024;57(11):2669-87 e6. Epub 20241011. doi: 10.1016/j.immuni.2024.09.007. PubMed PMID: 39395421; PMCID: PMC11578068.

11.       Richardson TE, Walker JM, Hambardzumyan D, Brem S, Hatanpaa KJ, Viapiano MS, Pai B, Umphlett M, Becher OJ, Snuderl M, McBrayer SK, Abdullah KG, Tsankova NM. Genetic and epigenetic instability as an underlying driver of progression and aggressive behavior in IDH-mutant astrocytoma. Acta Neuropathol. 2024;148(1):5. Epub 20240716. doi: 10.1007/s00401-024-02761-7. PubMed PMID: 39012509; PMCID: PMC11252228.

12.       Read RD, Tapp ZM, Rajappa P, Hambardzumyan D. Glioblastoma microenvironment-from biology to therapy. Genes Dev. 2024;38(9-10):360-79. Epub 20240625. doi: 10.1101/gad.351427.123. PubMed PMID: 38811170; PMCID: PMC11216181.

2023

13.       Shi X, Lingerak R, Herting CJ, Ge Y, Kim S, Toth P, Wang W, Brown BP, Meiler J, Sossey-Alaoui K, Buck M, Himanen J, Hambardzumyan D, Nikolov DB, Smith AW, Wang B. Time-resolved live-cell spectroscopy reveals EphA2 multimeric assembly. Science. 2023;382(6674):1042-50. Epub 20231116. doi: 10.1126/science.adg5314. PubMed PMID: 37972196; PMCID: PMC11114627.

14.       Sattiraju A, Kang S, Giotti B, Chen Z, Marallano VJ, Brusco C, Ramakrishnan A, Shen L, Tsankov AM, Hambardzumyan D, Friedel RH, Zou H. Hypoxic niches attract and sequester tumor-associated macrophages and cytotoxic T cells and reprogram them for immunosuppression. Immunity. 2023;56(8):1825-43 e6. Epub 20230713. doi: 10.1016/j.immuni.2023.06.017. PubMed PMID: 37451265; PMCID: PMC10527169.

15.       Ross JL, Hambardzumyan D. Et tu neutrophils? The brain reprograms neutrophils to facilitate tumor progression. Immunity. 2023;56(11):2469-71. doi: 10.1016/j.immuni.2023.10.006. PubMed PMID: 37967529.

16.       McSwain LF, Pillsbury CE, Haji-Seyed-Javadi R, Rath SK, Chen V, Huang T, Shahab SW, Kunhiraman H, Ross J, Price GA, Dey A, Hambardzumyan D, MacDonald T, Yu DS, Porter CC, Kenney AM. YB1 modulates the DNA damage response in medulloblastoma. Sci Rep. 2023;13(1):8087. Epub 20230519. doi: 10.1038/s41598-023-35220-6. PubMed PMID: 37208357; PMCID: PMC10199100.

17.       Jeon HM, Kim JY, Cho HJ, Lee WJ, Nguyen D, Kim SS, Oh YT, Kim HJ, Jung CW, Pinero G, Joshi T, Hambardzumyan D, Sakaguchi T, Hubert CG, McIntyre TM, Fine HA, Gladson CL, Wang B, Purow BW, Park JB, Park MJ, Nam DH, Lee J. Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling. Cancer Cell. 2023;41(8):1480-97 e9. Epub 20230713. doi: 10.1016/j.ccell.2023.06.007. PubMed PMID: 37451272; PMCID: PMC10530238.

18.       Friedmann-Morvinski D, Hambardzumyan D. Monocyte-neutrophil entanglement in glioblastoma. J Clin Invest. 2023;133(1). Epub 20230103. doi: 10.1172/JCI163451. PubMed PMID: 36594465; PMCID: PMC9797336.

19.       Chen Z, Soni N, Pinero G, Giotti B, Eddins DJ, Lindblad KE, Ross JL, Puigdelloses Vallcorba M, Joshi T, Angione A, Thomason W, Keane A, Tsankova NM, Gutmann DH, Lira SA, Lujambio A, Ghosn EEB, Tsankov AM, Hambardzumyan D. Monocyte depletion enhances neutrophil influx and proneural to mesenchymal transition in glioblastoma. Nat Commun. 2023;14(1):1839. Epub 20230403. doi: 10.1038/s41467-023-37361-8. PubMed PMID: 37012245; PMCID: PMC10070461.

20.       Chen Z, Giotti B, Kaluzova M, Vallcorba MP, Rawat K, Price G, Herting CJ, Pinero G, Cristea S, Ross JL, Ackley J, Maximov V, Szulzewsky F, Thomason W, Marquez-Ropero M, Angione A, Nichols N, Tsankova NM, Michor F, Shayakhmetov DM, Gutmann DH, Tsankov AM, Hambardzumyan D. A paracrine circuit of IL-1beta/IL-1R1 between myeloid and tumor cells drives genotype-dependent glioblastoma progression. J Clin Invest. 2023;133(22). Epub 20231115. doi: 10.1172/JCI163802. PubMed PMID: 37733448; PMCID: PMC10645395.

2022

21.       Tomita Y, Shimazu Y, Somasundaram A, Tanaka Y, Takata N, Ishi Y, Gadd S, Hashizume R, Angione A, Pinero G, Hambardzumyan D, Brat DJ, Hoeman CM, Becher OJ. A novel mouse model of diffuse midline glioma initiated in neonatal oligodendrocyte progenitor cells highlights cell-of-origin dependent effects of H3K27M. Glia. 2022;70(9):1681-98. Epub 20220507. doi: 10.1002/glia.24189. PubMed PMID: 35524725; PMCID: PMC9546478.

22.       McSwain LF, Parwani KK, Shahab SW, Hambardzumyan D, MacDonald TJ, Spangle JM, Kenney AM. Medulloblastoma and the DNA Damage Response. Front Oncol. 2022;12:903830. Epub 20220607. doi: 10.3389/fonc.2022.903830. PubMed PMID: 35747808; PMCID: PMC9209741.

23.       Bae E, Huang P, Muller-Greven G, Hambardzumyan D, Sloan AE, Nowacki AS, Marko N, Carlin CR, Gladson CL. Integrin alpha3beta1 promotes vessel formation of glioblastoma-associated endothelial cells through calcium-mediated macropinocytosis and lysosomal exocytosis. Nat Commun. 2022;13(1):4268. Epub 20220725. doi: 10.1038/s41467-022-31981-2. PubMed PMID: 35879332; PMCID: PMC9314429.

2021

24.       Ross JL, Velazquez Vega J, Plant A, MacDonald TJ, Becher OJ, Hambardzumyan D. Tumour immune landscape of paediatric high-grade gliomas. Brain. 2021;144(9):2594-609. doi: 10.1093/brain/awab155. PubMed PMID: 33856022; PMCID: PMC8536940.

25.       Ross JL, Chen Z, Herting CJ, Grabovska Y, Szulzewsky F, Puigdelloses M, Monterroza L, Switchenko J, Wadhwani NR, Cimino PJ, Mackay A, Jones C, Read RD, MacDonald TJ, Schniederjan M, Becher OJ, Hambardzumyan D. Platelet-derived growth factor beta is a potent inflammatory driver in paediatric high-grade glioma. Brain. 2021;144(1):53-69. doi: 10.1093/brain/awaa382. PubMed PMID: 33300045; PMCID: PMC7954387.

26.       Puigdelloses M, Garcia-Moure M, Labiano S, Laspidea V, Gonzalez-Huarriz M, Zalacain M, Marrodan L, Martinez-Velez N, De la Nava D, Ausejo I, Hervas-Stubbs S, Herrador G, Chen Z, Hambardzumyan D, Patino Garcia A, Jiang H, Gomez-Manzano C, Fueyo J, Gallego Perez de Larraya J, Alonso M. CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models. J Immunother Cancer. 2021;9(7). Epub 2021/07/21. doi: 10.1136/jitc-2021-002644. PubMed PMID: 34281988.

27.       Price G, Bouras A, Hambardzumyan D, Hadjipanayis CG. Current knowledge on the immune microenvironment and emerging immunotherapies in diffuse midline glioma. EBioMedicine. 2021;69:103453. Epub 20210619. doi: 10.1016/j.ebiom.2021.103453. PubMed PMID: 34157482; PMCID: PMC8220552.

28.       Kenchappa RS, Liu Y, Argenziano MG, Banu MA, Mladek AC, West R, Luu A, Quinones-Hinojosa A, Hambardzumyan D, Justilien V, Leitges M, Sarkaria JN, Sims PA, Canoll P, Murray NR, Fields AP, Rosenfeld SS. Protein kinase C(iota) and SRC signaling define reciprocally related subgroups of glioblastoma with distinct therapeutic vulnerabilities. Cell Rep. 2021;37(8):110054. doi: 10.1016/j.celrep.2021.110054. PubMed PMID: 34818553; PMCID: PMC9845019.

29.       Chen Z, Hambardzumyan D. Macrophage-tumor cell intertwine drives the transition into a mesenchymal-like cellular state of glioblastoma. Cancer Cell. 2021;39(6):743-5. Epub 20210603. doi: 10.1016/j.ccell.2021.05.003. PubMed PMID: 34087163.

30.       Buonfiglioli A, Hambardzumyan D. Macrophages and microglia: the cerberus of glioblastoma. Acta Neuropathol Commun. 2021;9(1):54. Epub 2021/03/27. doi: 10.1186/s40478-021-01156-z. PubMed PMID: 33766119; PMCID: PMC7992800.

31.       Alghamri MS, McClellan BL, Avvari RP, Thalla R, Carney S, Hartlage CS, Haase S, Ventosa M, Taher A, Kamran N, Zhang L, Faisal SM, Nunez FJ, Garcia-Fabiani MB, Al-Holou WN, Orringer D, Hervey-Jumper S, Heth J, Patil PG, Eddy K, Merajver SD, Ulintz PJ, Welch J, Gao C, Liu J, Nunez G, Hambardzumyan D, Lowenstein PR, Castro MG. G-CSF secreted by mutant IDH1 glioma stem cells abolishes myeloid cell immunosuppression and enhances the efficacy of immunotherapy. Sci Adv. 2021;7(40):eabh3243. Epub 20210929. doi: 10.1126/sciadv.abh3243. PubMed PMID: 34586841; PMCID: PMC8480930.

2020

32.       Haage V, Semtner M, Vidal RO, Hernandez DP, Pong WW, Chen Z, Hambardzumyan D, Magrini V, Ly A, Walker J, Mardis E, Mertins P, Sauer S, Kettenmann H, Gutmann DH. Correction to: Comprehensive gene expression meta-analysis identifies signature genes that distinguish microglia from peripheral monocytes/macrophages in health and glioma. Acta Neuropathol Commun. 2020;8(1):1. Epub 20200108. doi: 10.1186/s40478-019-0875-3. PubMed PMID: 31915069; PMCID: PMC6947830.

33.       Elmadany N, de Almeida Sassi F, Wendt S, Logiacco F, Visser J, Haage V, Hernandez DP, Mertins P, Hambardzumyan D, Wolf S, Kettenmann H, Semtner M. The VGF-derived Peptide TLQP21 Impairs Purinergic Control of Chemotaxis and Phagocytosis in Mouse Microglia. J Neurosci. 2020;40(17):3320-31. Epub 20200214. doi: 10.1523/JNEUROSCI.1458-19.2020. PubMed PMID: 32060170; PMCID: PMC7178903.

34.       De Boeck A, Ahn BY, D'Mello C, Lun X, Menon SV, Alshehri MM, Szulzewsky F, Shen Y, Khan L, Dang NH, Reichardt E, Goring KA, King J, Grisdale CJ, Grinshtein N, Hambardzumyan D, Reilly KM, Blough MD, Cairncross JG, Yong VW, Marra MA, Jones SJM, Kaplan DR, McCoy KD, Holland EC, Bose P, Chan JA, Robbins SM, Senger DL. Glioma-derived IL-33 orchestrates an inflammatory brain tumor microenvironment that accelerates glioma progression. Nat Commun. 2020;11(1):4997. Epub 20201005. doi: 10.1038/s41467-020-18569-4. PubMed PMID: 33020472; PMCID: PMC7536425.

35.       Chen Z, Herting CJ, Ross JL, Gabanic B, Puigdelloses Vallcorba M, Szulzewsky F, Wojciechowicz ML, Cimino PJ, Ezhilarasan R, Sulman EP, Ying M, Ma'ayan A, Read RD, Hambardzumyan D. Genetic driver mutations introduced in identical cell-of-origin in murine glioblastoma reveal distinct immune landscapes but similar response to checkpoint blockade. Glia. 2020;68(10):2148-66. Epub 20200708. doi: 10.1002/glia.23883. PubMed PMID: 32639068; PMCID: PMC7512141.

36.       Alexander J, LaPlant QC, Pattwell SS, Szulzewsky F, Cimino PJ, Caruso FP, Pugliese P, Chen Z, Chardon F, Hill AJ, Spurrell C, Ahrendsen D, Pietras A, Starita LM, Hambardzumyan D, Iavarone A, Shendure J, Holland EC. Multimodal single-cell analysis reveals distinct radioresistant stem-like and progenitor cell populations in murine glioma. Glia. 2020;68(12):2486-502. Epub 20200704. doi: 10.1002/glia.23866. PubMed PMID: 32621641; PMCID: PMC7586969.

2019

37.       Nunez FJ, Mendez FM, Kadiyala P, Alghamri MS, Savelieff MG, Garcia-Fabiani MB, Haase S, Koschmann C, Calinescu AA, Kamran N, Saxena M, Patel R, Carney S, Guo MZ, Edwards M, Ljungman M, Qin T, Sartor MA, Tagett R, Venneti S, Brosnan-Cashman J, Meeker A, Gorbunova V, Zhao L, Kremer DM, Zhang L, Lyssiotis CA, Jones L, Herting CJ, Ross JL, Hambardzumyan D, Hervey-Jumper S, Figueroa ME, Lowenstein PR, Castro MG. IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response. Sci Transl Med. 2019;11(479). doi: 10.1126/scitranslmed.aaq1427. PubMed PMID: 30760578; PMCID: PMC6400220.

38.       Maximov V, Chen Z, Wei Y, Robinson MH, Herting CJ, Shanmugam NS, Rudneva VA, Goldsmith KC, MacDonald TJ, Northcott PA, Hambardzumyan D, Kenney AM. Tumour-associated macrophages exhibit anti-tumoural properties in Sonic Hedgehog medulloblastoma. Nat Commun. 2019;10(1):2410. Epub 20190603. doi: 10.1038/s41467-019-10458-9. PubMed PMID: 31160587; PMCID: PMC6546707.

39.       Mastrella G, Hou M, Li M, Stoecklein VM, Zdouc N, Volmar MNM, Miletic H, Reinhard S, Herold-Mende CC, Kleber S, Eisenhut K, Gargiulo G, Synowitz M, Vescovi AL, Harter PN, Penninger JM, Wagner E, Mittelbronn M, Bjerkvig R, Hambardzumyan D, Schuller U, Tonn JC, Radke J, Glass R, Kalin RE. Targeting APLN/APLNR Improves Antiangiogenic Efficiency and Blunts Proinvasive Side Effects of VEGFA/VEGFR2 Blockade in Glioblastoma. Cancer Res. 2019;79(9):2298-313. Epub 20190204. doi: 10.1158/0008-5472.CAN-18-0881. PubMed PMID: 30718358.

40.       Kaffes I, Szulzewsky F, Chen Z, Herting CJ, Gabanic B, Velazquez Vega JE, Shelton J, Switchenko JM, Ross JL, McSwain LF, Huse JT, Westermark B, Nelander S, Forsberg-Nilsson K, Uhrbom L, Maturi NP, Cimino PJ, Holland EC, Kettenmann H, Brennan CW, Brat DJ, Hambardzumyan D. Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors. Oncoimmunology. 2019;8(11):e1655360. Epub 20190822. doi: 10.1080/2162402X.2019.1655360. PubMed PMID: 31646100; PMCID: PMC6791439.

41.       Herting CJ, Chen Z, Maximov V, Duffy A, Szulzewsky F, Shayakhmetov DM, Hambardzumyan D. Tumour-associated macrophage-derived interleukin-1 mediates glioblastoma-associated cerebral oedema. Brain. 2019;142(12):3834-51. doi: 10.1093/brain/awz331. PubMed PMID: 31665239; PMCID: PMC6906596.

42.       Chen Z, Ross JL, Hambardzumyan D. Intravital 2-photon imaging reveals distinct morphology and infiltrative properties of glioblastoma-associated macrophages. Proc Natl Acad Sci U S A. 2019;116(28):14254-9. Epub 20190624. doi: 10.1073/pnas.1902366116. PubMed PMID: 31235603; PMCID: PMC6628659.

43.       Boyd NH, Walker K, Ayokanmbi A, Gordon ER, Whetsel J, Smith CM, Sanchez RG, Lubin FD, Chakraborty A, Tran AN, Herting C, Hambardzumyan D, Yancey Gillespie G, Hackney JR, Cooper SJ, Jiao K, Hjelmeland AB. Chromodomain Helicase DNA-Binding Protein 7 Is Suppressed in the Perinecrotic/Ischemic Microenvironment and Is a Novel Regulator of Glioblastoma Angiogenesis. Stem Cells. 2019;37(4):453-62. Epub 20190124. doi: 10.1002/stem.2969. PubMed PMID: 30629778; PMCID: PMC6596424.

44.       Akamandisa MP, Nie K, Nahta R, Hambardzumyan D, Castellino RC. Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma. Neuro Oncol. 2019;21(6):786-99. doi: 10.1093/neuonc/noz053. PubMed PMID: 30852603; PMCID: PMC6556861.